Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-beta1 that can inhibit the release of active TGF-beta1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors[1][2].
Molecular Weight:
(146.22 kDa)
Purity:
99.25
CAS Number:
[2412004-88-5]
Target:
TGF-beta/Smad
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted